Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Merck & Co., Inc. (MRK) is 7/10.
Merck delivered total revenue of $16.3 billion, up 5% (3% ex-FX), led by the KEYTRUDA family at $8 billion (+8%, including roughly $250 million of favorable U.S. purchase timing) and WELIREG at $199 million (+43%), with Animal Health up 6% and newer launches WINREVAIR ($525 million) and CAPVAXIVE ($142 million) continuing to scale. GARDASIL remained the principal drag at $1.1 billion, down 22% on expected China and Japan weakness. A $9 billion one-time charge tied to the Cidara Therapeutics acquisition drove a reported loss of $1.28 per share (a $3.62 per share impact); excluding it, operating expenses grew just 2% and underlying profitability was intact. Management narrowed and raised the midpoint of full-year 2026 guidance to $65.8-$67 billion in revenue (1-3% growth) and $5.04-$5.16 in EPS, excluding the pending Terns Pharmaceuticals acquisition and its expected $5.8 billion charge.
Scored from Merck & Co., Inc.’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $15.62B | +6.8% | $1.48 | +408.3% | 27.8% | 24.0% | $2.51B |
| FY2025 Q1 | $15.62B | -1.0% | $2.01 | +7.5% | 43.0% | 32.5% | $1.17B |
| FY2025 Q2 | $15.80B | -1.9% | $1.76 | -17.8% | 40.2% | 28.0% | $2.53B |
| FY2025 Q3 | $17.18B | +3.2% | $2.32 | +87.1% | 43.4% | 33.7% | $6.83B |
| FY2025 Q4 | $16.32B | +4.5% | $1.19 | -19.6% | 37.7% | 18.2% | $1.82B |
| FY2026 Q1 | $16.29B | +4.3% | $-1.72 | -185.6% | -11.6% | -26.0% | $2.93B |
| FY2026 Q2 | $16.61B | +5.1% | $-0.54 | -130.7% | -2.6% | -8.0% | $4.48B |
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.